Insulin Pumps available
There are a number of insulin pumps available in the UK today each offering different features and benefits. Not all pumps will be available in every area.
The key is to work with your diabetes team to find the pump that is right for you.
Learn more about the pumps available in Scotland at present:
- Medtronic Minimed 640G System
- Roche – Accu Chek Insight pump
- Medtronic Veo
- Animas Vibe
- Roche – Accu-Chek Combo
Other pumps available in the UK:
- Dana Diabecare R – not normally funded by NHS Scotland
- OmniPod – not normally funded by NHS Scotland
- CellNovo management system – phased launch in Wales and England
Pumps available throughout the world:
- Medtronic Revel (US version similar to Medtronic Veo)
- Medtronic MiniMed 530G
- Medtronic MiniMed 630G
- Medtronic MiniMed 670G
- OneTouch Ping (US version similar to Animas Vibe)
- Tandem t:slim
- Asante Snap
Coming soon to the UK (hopefully!)
Medtronic MiniMed 670G (Hybrid Closed-Loop Control and Enite 3 system)
mylife YpsoPump (simplifying the pump – not good reviews from bloggers who have more information on it, but may be more suitable for people with Type 2 Diabetes, we won’t know till it’s out and people have experienced this pump)
Animas Vibe Plus – First Pump Integrated with the Dexcom G5® Mobile
Animas – Hypo-Hyper Minimiser (HHM) claiming to aim for “Cruise Control”
Hypoglycaemic-Hyperglycaemic system Minimiser (HHM) developed by Animas Corporation in collaboration with the Juvenile Diabetes Research Foundation (JDRF). It is based on a closed loop technique consisting of an Animas insulin pump with integrated Dexcom CGM. The accuracy and reliability of both products is now well documented. The system’s unique dosing algorithm designed to predict episodes of high or low blood sugar (hypo or hyperglycaemia).
Our ambition is to get a predictive closed-loop system to market as quickly as possible – Dr. Venugopalan
In 2010, Animas first teamed up with the JDRF to develop an automated closed-loop insulin delivery system to improve glucose control in patients with type 1 diabetes. First real indications of the HHM started in June 2012, when results from the first human trials were reported at the 2012 ADA Scientific Sessions. Further indication of it getting closer were at the ADDT in 2013, when Animas displayed two posters on the results of the trials. Since then a feasibility study of the predictive Hypoglycemia – Hyperglycemia Minimiser System in development was conducted in 20 adults with type 1 diabetes and designed to investigate the system’s ability to adjust insulin dosing to proactively mitigate hypoglycaemia and hyperglycaemia. Progress has been pleasing.
In 2014 – Closed-Loop Control Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a Feasibility Study (Finan et al, “Closed Loop Control Performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) System in a Feasibility Study”, Journal of Diabetes Science & Technology 2014. Vol. 8(1) 35-42) Found the results of the study indicating that the HHM System is a feasible foundation for development of a closed-loop control insulin delivery device; further studies were under way.
In 2015, a study of twelve adults with type 1 diabetes in closed-loop in a clinical research center for approximately 24 hours (J Diabetes Sci Technol. 2015 Jun 30;10(1):104-10. doi: 10.1177/1932296815593292) Results were good.
The conclusion of the study:
The Hypo Minimiser’s controller took preemptive action to prevent hypoglycemia based on predicted changes in CGM glucose levels. The most aggressive setting was quickest to take action to reduce insulin delivery below basal and achieved the best glucose metrics.
Read the full journey up till now – Animas Hypoglycaemia-Hyperglycaemia Minimiser New Insulin Pump System
Keep an eye on Bigfoot Biomedical for exciting future developments